Medical cost savings in Sakado City and worldwide achieved by preventing disease by folic acid fortification

Congenit Anom (Kyoto). 2017 Sep;57(5):157-165. doi: 10.1111/cga.12215. Epub 2017 Apr 4.

Abstract

The introduction of mandatory fortification of grains with folate in 1998 in the United States resulted in 767 fewer spina bifida cases annually and a cost saving of $603 million per year. However, far more significant medical cost savings result from preventing common diseases, including myocardial infarction, stroke, dementia and osteoporosis. A cost-effectiveness analysis showed a gain of 266 649 quality-adjusted life-years and $3.6 billion saved annually, mainly due to the reduction of cardiac infarction. The recommended folate intake in Japan is 240 μg/day whereas it is 400 μg/day internationally. Our Sakado Folate Project targeted individuals with genetic polymorphism of methylenetetrahydrofolate reductase or with hyperhomocysteinemia. Using, for example, folate-fortified rice, resulted in an increase in serum folate and a decrease in serum homocysteine in the participants, and reduced medical costs were achieved by decreasing myocardial infarction, stroke, dementia and fracture. Due to the small population of Sakado City (approximately 101 000) and small number of births (693) in 2015, a decrease in spina bifida could not be confirmed but there was a significant decrease in the number of very low birthweight infants. The genome notification of subjects was effective in motivating intake of folate, but the increase in serum folate (from 17.4 to 22.5 nmol/L, 129%) was less than that observed following compulsory folic acid fortification of cereals in the USA (from 12.1 to 30.2 nmol/L, 149.6%). Mandatory folic acid fortification is cheap in decreasing medical costs and is thus recommended in Japan.

Keywords: folate; fortification; genetic polymorphism; medical cost.

Publication types

  • Review

MeSH terms

  • Adult
  • Cost-Benefit Analysis
  • Dietary Supplements*
  • Female
  • Folic Acid / administration & dosage
  • Folic Acid / metabolism*
  • Folic Acid Deficiency / economics*
  • Folic Acid Deficiency / epidemiology
  • Folic Acid Deficiency / metabolism
  • Folic Acid Deficiency / prevention & control
  • Food, Fortified / economics*
  • Food, Fortified / statistics & numerical data
  • Humans
  • Infant, Newborn
  • Japan / epidemiology
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics
  • Methylenetetrahydrofolate Reductase (NADPH2) / metabolism
  • Myocardial Infarction / economics*
  • Myocardial Infarction / epidemiology
  • Myocardial Infarction / metabolism
  • Myocardial Infarction / prevention & control
  • Polymorphism, Genetic
  • Pregnancy
  • Prevalence
  • Recommended Dietary Allowances
  • Spinal Dysraphism / economics*
  • Spinal Dysraphism / epidemiology
  • Spinal Dysraphism / metabolism
  • Spinal Dysraphism / prevention & control

Substances

  • Folic Acid
  • MTHFR protein, human
  • Methylenetetrahydrofolate Reductase (NADPH2)